Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An assessment of imaging and circulating biomarkers in patients with metastatic colorectal carcinoma treated with the anti-vascular endothelial growth factor (anti-VEGF) antibody, bevacizumab.

Next Previous
Trial Profile

An assessment of imaging and circulating biomarkers in patients with metastatic colorectal carcinoma treated with the anti-vascular endothelial growth factor (anti-VEGF) antibody, bevacizumab.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms TRAVASTIN-1

Most Recent Events

  • 02 Jun 2017 Results of inter-tumor validation assessing plasma Tie2 as the vascular response biomarker for bevacizumab, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
  • 25 Oct 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
  • 14 Sep 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top